Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adipose tissue-derived stem cells for veterinary use

An adipose tissue and stem cell technology, which can be used in drug combinations, medical raw materials derived from mammals, medical preparations containing active ingredients, etc., and can solve problems such as taking too long

Inactive Publication Date: 2014-06-04
CELL4VET
View PDF17 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For animal clinics, autologous treatment programs take too long for both veterinarians and pet owners

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adipose tissue-derived stem cells for veterinary use
  • Adipose tissue-derived stem cells for veterinary use
  • Adipose tissue-derived stem cells for veterinary use

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0079] The preparation of cell or tissue based therapeutic compositions is well known in the art. The composition can be formulated in a pharmaceutically acceptable medium. Cells can be in solution or embedded in a matrix. The preparation of therapeutic compositions having bioactive agents (eg, growth factors) as active ingredients is well known in the art. The active therapeutic ingredient is usually mixed with an excipient or vehicle which is pharmaceutically acceptable and compatible with the active ingredient. In addition, the composition, if desired, can contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, which enhance the effectiveness of the active ingredients.

[0080] Bioactive agents can be formulated into therapeutic compositions in the form of neutralized pharmaceutically acceptable salts. Pharmaceutically acceptable salts include acid addition salts (formed with free amino groups of peptide or antibody mole...

example 1

[0147] Example 1 Experimental Treatment of Canine Urinary Incontinence Using Adipose Tissue-Derived Stem Cells

[0148] Materials and methods

[0149] animal selection

[0150] Female dogs with overt UI symptoms were selected for this study. These symptoms include dribbling, loss of voluntary control, and / or urine burn dermatitis. To ensure that an individual's UI symptoms are due to a urethral defect, they must demonstrate responsiveness to PPA treatment. Each owner also agrees to enter this experimental study by signing a consent form stating that (1) the dog will undergo a test injection of ADSC in the hind leg to ensure that there is no immune response, (2) the PPA treatment of the dog will be Withdrawal for a number of days (up to 1 week) to allow UI symptoms to reappear, (3) dog must demonstrate reappearance of UI symptoms at least 3 days before undergoing ADSC treatment, and (4) if owner does not wish to reappear after PPA is withdrawn and / or Or caring for a dog a...

example 2

[0158] Example 2 Using ADSCs to Treat Osteoarthritis

[0159] treatment procedure

[0160] Although OA can afflict virtually any joint, it is most commonly associated with the knees and hips of the hind limbs. Injecting ADSCs into the joint is similar to injecting corticosteroids, except that a cell suspension is used instead of steroids. The volume of the cell suspension and the number of cells vary proportionally with the size of the individual. As an example, a 20kg dog will receive five million ADSCs per joint in 0.5ml PBS. After treatment, the owner is advised to walk the dog on a leash for 30 minutes a day. Dogs were allowed to continue taking any oral medications taken prior to ADSC treatment. Any intra-articular therapy prior to ADSC treatment should be discontinued.

[0161] Post-Treatment Evaluation

[0162] Animal evaluation will include medical records, physical examination, and lameness examination including joint mobility and pain documentation during man...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to adipose tissue-derived stem cells for veterinary use. The invention provides compositions and methods for making and using the adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures and for treatment of "dry eye" conditions, acute renal failure, and chronic renal failure in non-human mammals.

Description

[0001] Cross References to Related Applications [0002] This application is a continuation-in-part of U.S. Application No. 12 / 997,067, filed February 14, 2011, which is the national phase of International Application No. PCT / US2009 / 046587, filed June 8, 2009 , said International Application asserting U.S. Provisional Application No. 61 / 060,701 filed June 11, 2008 and U.S. Provisional Application No. 61 / 168,148 filed April 9, 2009 under 35 U.S.C. § 119(e) number, the contents of each of which are incorporated herein by reference in their entirety. technical field [0003] The present invention provides compositions and methods for making and using adipose-derived stem cells to treat various medical conditions in non-human mammals, including bone fractures, "dry eye conditions," chronic renal failure, and acute renal failure. Background technique [0004] Adipose tissue contains a stromal vascular fraction (SVF) from which pluripotent cells have been isolated. These cells ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/12A61P19/08A61P27/02A61P13/12A61K35/28
Inventor 林庆顺吕福泰林桂廷
Owner CELL4VET
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com